Group 2354.png

Management and escalation

Management of Lipid-Lowering Therapy for Patients With ACS1

image 25.png

*Nonstatin LDL-lowering therapy: ezetimibe, PCSK9 inhibitor (alirocumab, evolocumab and inclisiran), and/or bempedoic acid1

EDA Approval No: WF0424OA5708/042026 EDA Invalidation Date:06/04/2027

References

  1. Rao SV, O’Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, Baber U, Baker H, Cohen MG, Cruz-Ruiz M, Davis LL. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2025 Jun 10;85(22):2135-237. Available at: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001309 . Last accessed:16/09/2025.

Adverse Events Reporting

We encourage using the following Electronic reporting tool for reporting into the safety database directly:
If the electronic reporting tool is not working - please use the following: https://www.report.novartis.com
1 - Generic Mailbox: [email protected]
2 - CISCO: +20 2 2 2861000: Press 3 for Adverse Events Reporting